Dhruva Space to deploy two Australian payloads using its home-built satellite platform
The Hyderabad-based start-up will launch payloads from Australia's Akula Tech and Esper satellites aboard its P-30 satellite platform on a SpaceX Falcon 9 rocket in Q3 of the current fiscal. AI payload Nexus-01 (Akula Tech) and hyperspectral imager OTR-2 (Esper) will fly on Dhruva's P-30 platform, which was successfully tested on ISRO's POEM-3 mission in January 2024.
The LEAP-1 mission is officially slated to launch aboard SpaceX's Falcon 9 in Q3 2025, marking not just a significant Indo-Australian collaboration, but also growing support from the United States in Dhruva Space's global commercial journey, the company said.
"Following a successful qualification of the P-30 onboard ISRO's PSLV-C58, Dhruva Space is excited to take its indigenously developed P-30 satellite platform to the global market," said Sanjay Nekkanti, CEO and co-founder of Dhruva Space.
Dhruva Space's hosted payload offering LEAP (Launching Expeditions for Aspiring Payloads) integrates Ground Station-as-a-Service (GSaaS) and its proprietary Integrated Space Operations and Command Suite (ISOCS) for real-time mission management and payload data downlinking.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
12 minutes ago
- Mint
Global markets today: Nikkei 225, Kospi rises after Trump increases tariffs on Indian exports
Global markets today: Asian markets moved higher after U.S. President Donald Trump revealed intentions to sharply increase tariffs on Indian exports to the U.S. Trump announced on Monday that he plans to significantly increase tariffs on Indian goods in response to India's imports of Russian oil. In turn, New Delhi described the U.S. president's move as 'unjustified' and stated it would take steps to protect its interests. 'India is not only buying massive amounts of Russian Oil, they are then, for much of the Oil purchased, selling it on the Open Market for big profits,' Trump wrote on the social media platform Truth Social. Japan's Nikkei 225 advanced by 0.54 per cent, and the Topix edged up 0.45 per cent. South Korea's Kospi climbed 1.77 per cent, while the Kosdaq, focused on small-cap stocks, rose 1.83 per cent. Australia's S&P/ASX 200 also registered a gain of 0.84 per cent. On Monday, all three major U.S. stock indexes posted their biggest single-day percentage gains since May 27, as investors looked for buying opportunities following the previous session's selloff and increased expectations of a September interest rate cut due to weaker-than-anticipated jobs data released on Friday. The Dow Jones Industrial Average rose by 585.06 points, or 1.34 per cent, to close at 44,173.64. The S&P 500 advanced 91.93 points, or 1.47 per cent, to 6,329.94, while the Nasdaq Composite surged 403.45 points, or 1.95 per cent, finishing at 21,053.58. The second-quarter U.S. earnings season is nearing its end, but investors are still anticipating key reports this week from companies such as Walt Disney, opens new tab. Tesla shares climbed 2.2 per cent after the electric car company awarded CEO Elon Musk 96 million shares, valued at approximately $29 billion. (With inputs from agencies) Disclaimer: This story is for educational purposes only. The views and recommendations above are those of individual analysts or broking companies, not Mint. We advise investors to check with certified experts before making any investment decisions.
Economic Times
15 minutes ago
- Economic Times
Hims & Hers Q2 revenue drop shakes stock—Hims crashes 11% after first-ever revenue decline, is the weight-loss drug hype finally fading?
Hims & Hers Health (NYSE: HIMS) saw its stock plunge over 11% after the company reported its Q2 2025 earnings, marking its first-ever sequential revenue decline. While revenue jumped 73% year-over-year to $544.8 million, it still fell short of Wall Street's expectations of $552 million, and notably dropped from $586 million in Q1. The miss has rattled investor confidence, especially as GLP-1 weight-loss drug sales, a key growth driver, showed signs of slowing amid regulatory pressure and legal setbacks. Synopsis Hims & Hers stock dropped a sharp 11% after the company missed Q2 2025 revenue estimates, raising concerns about its booming weight-loss drug business. While year-over-year sales jumped 73%, revenue fell sequentially for the first time, causing investor worry. The company brought in $544.8 million, short of forecasts, with much of it tied to its GLP-1 obesity drug offerings. Hims & Hers Health (NYSE: HIMS), the fast-growing telehealth company known for its personalized care plans and buzzy entry into the weight-loss market, saw its stock drop by over 11% after reporting second-quarter 2025 earnings. While revenue jumped 73% year-over-year, the company missed Wall Street expectations and posted its first-ever sequential revenue decline, raising questions about the future of its GLP-1 obesity drug business. ADVERTISEMENT Despite its rapid annual growth, Hims & Hers posted Q2 revenue of $544.8 million, missing the analyst estimate of $552 million. The real concern? Revenue dropped from $586 million in Q1, marking the first quarter-over-quarter decline since the company went public. The stock currently trades at $63.35, regaining some ground after hitting an intraday low of $54.82. Despite opening at $64.00, it remains volatile, with an intraday high of $65.54. ALSO READ: Bullish IPO debut: Peter Thiel-backed crypto giant targets $4.2B valuation—is the new crypto wave knocking on Wall Street's door? The market reacted sharply to the company's revenue miss—$544.8 million vs. $552 million expected—even though earnings per share beat expectations and subscriber numbers remained strong. Most of the company's revenue stemmed from its GLP-1-based obesity and diabetes treatments, a booming but increasingly scrutinized business segment. ALSO READ: Palantir stock soars after $1B Q2 earnings crush forecasts as AI demand fuels 110% YTD surge—now S&P 500's top performer ADVERTISEMENT With regulatory pressures, lawsuits from Novo Nordisk, and tighter FDA rules on compounded semaglutide, Hims faces headwinds in its fastest-growing segment. However, with a market cap of over $6.5 billion, a P/E ratio of 39.93, and forward-looking confidence via its Zava acquisition, the company is still betting big on growth in both the U.S. and Europe. Current Price : $63.35 : $63.35 Day Range : $54.82 – $65.54 : $54.82 – $65.54 Open : $64.00 : $64.00 Market Cap: $6.56 Billion P/E Ratio : 39.93 : 39.93 Volume: 35.5M Investors were caught off guard, as the slowdown came amid soaring demand for weight-loss drugs like semaglutide, a compound similar to the active ingredient in Wegovy and Ozempic. ADVERTISEMENT On the profit front, Hims reported an adjusted EPS of $0.19, beating the Street's expectation of $0.15. However, the revenue miss overshadowed this earnings win. Investors appeared more concerned about the underlying business momentum, particularly in the obesity treatment space, which has been a major driver of Hims' recent growth. ADVERTISEMENT Hims' biggest growth story in recent quarters has been its expansion into GLP-1 weight-loss treatments, which brought in around $190 million in Q2 alone. However, a few red flags have emerged: Regulatory uncertainty : With the FDA rolling back flexibility on compounded versions of semaglutide, questions are mounting about how long Hims can rely on this segment for revenue. : With the FDA rolling back flexibility on of semaglutide, questions are mounting about how long Hims can rely on this segment for revenue. Legal challenges : The company recently ended its supply relationship with Novo Nordisk , the maker of Wegovy, and is now facing lawsuits over how it marketed compounded alternatives. : The company recently ended its supply relationship with , the maker of Wegovy, and is now facing lawsuits over how it marketed compounded alternatives. Competitive pressure: Big players like Eli Lilly and Novo Nordisk are dominating the branded drug market, making it harder for telehealth companies offering generics to compete on pricing and trust. Despite the Q2 shortfall, Hims & Hers stuck to its full-year outlook. The company reaffirmed its 2025 guidance of $2.3 billion to $2.4 billion in revenue and $295 million to $335 million in adjusted EBITDA. ADVERTISEMENT A big reason? The Zava acquisition, a European telehealth platform, which is expected to contribute around $50 million in new revenue this year. This suggests Hims is betting heavily on international growth to offset some of its domestic uncertainty. One bright spot in the report was Hims' growing subscriber base. The company now serves over 2.4 million active subscribers, with nearly 70% enrolled in personalized treatment plans that span weight loss, hair care, sexual health, and mental wellness. CEO Andrew Dudum emphasized that the company is leaning deeper into its long-term strategy of personalized digital healthcare, aiming to build loyalty and customer lifetime value across multiple product categories. If you're following Hims & Hers stock or investing in telehealth companies focused on the obesity drug boom, here are four key things to monitor: Future of compounded GLP-1s: Regulatory and legal outcomes could limit Hims' ability to sell compounded semaglutide at scale. Profitability trends: Will margins hold up as more competition floods the market and Hims scales its personalized offerings? Subscriber growth and retention: Continued engagement in non-weight loss categories will be key to long-term stability. Zava integration: The success or failure of this acquisition could make or break Hims' international ambitions. Hims & Hers Health has come a long way as a digital-first wellness brand with a bold strategy around weight-loss drugs and personalized healthcare. But the 11% stock drop shows investor sentiment is shifting, especially as its flagship obesity business faces regulatory hurdles and supply uncertainty. For now, the company's strong year-over-year growth and firm 2025 guidance offer some reassurance. But with rising competition, tighter FDA rules, and legal pressure, Hims will need to prove that its success isn't just tied to a single product wave—but a durable, trusted digital care ecosystem. What caused Hims & Hers stock to fall 11% after Q2 earnings? The company missed revenue estimates and saw its first-ever sequential drop in sales. Is the Hims weight-loss drug business facing trouble in 2025? Yes, due to FDA scrutiny and legal issues around compounded semaglutide. (You can now subscribe to our Economic Times WhatsApp channel) (Catch all the US News, UK News, Canada News, International Breaking News Events, and Latest News Updates on The Economic Times.) Download The Economic Times News App to get Daily International News Updates. NEXT STORY
Mint
42 minutes ago
- Mint
The CEO shuffle: Massive disruption prompts global hunt for agile, adaptive leadership
The global economic scenario is unraveling at breakneck speed, with artificial intelligence (AI) and tariff wars its most visible drivers. From boardrooms in Mumbai to Cincinnati, companies are reckoning with what US politician Donald Rumsfeld once called the 'unknown unknowns". One clear sign of this reckoning is the sudden, sometimes opaque leadership changes at companies. Take Procter & Gamble (P&G) and Jaguar Land Rover (JLR), both of which just announced unexpected changes at the top. At P&G, chief operating officer Shailesh Jejurikar was named as the new CEO while at JLR Adrian Mardell will step down after a controversial makeover of the brand went down badly. India, too, hasn't been immune to the need for fresh leaders. Last week, Rohit Jawa stepped down as CEO of Hindustan Unilever (HUL) after just two years in the job. Since the beginning of this year, there have been similar leadership transitions at companies ranging from DMart to Page Industries. These moves aren't just routine corporate reshuffles, but a response to huge disruptions in the way business has been done for decades. Indeed, leadership changes at such bastions of corporate continuity like HUL suggest that business models which served well for decades may no longer suffice. And while AI and the Trump tariffs are in the spotlight, the forces at work are broader and more complex. Look no further than developments at Tata Consultancy Services (TCS), India's largest IT services company and among the country's biggest employers, which recently announced what may be its largest layoff exercise to date. The last time a Tata Group company initiated job cuts of this scale was in the 1990s, when Tata Steel, then the conglomerate's flagship, slashed a third of its workforce under its new leader Ratan Tata. It was a move that marked a fundamental pivot away from the steel company's past and toward a tech-enabled, globally competitive model of making steel. TCS, the group's crown jewel for the last two decades, appears to be navigating a similar inflection point. The company's CEO K. Krithivasan has been quite explicit in clarifying that the shake-up is not primarily due to AI, but to seismic changes in client expectations and the global delivery landscape. In other words, these are not reactions to short-term turbulence. They are structural responses to a market that is altering in ways even the most advanced forecasting models failed to predict. A key element of this flux is changing consumer behaviour which has become markedly more complex, and, in many cases, more frugal. Companies such as Nestle, ITC, and HUL in India have, for over two years, cautioned about softening demand, especially in their lower-priced segments. But while most companies still maintain that it is a blip, there is reason to believe that this may be the new normal. India's markets, often assumed to be bottomless reservoirs of demand for multinationals, are showing signs of maturity and saturation. Maruti Suzuki chairman R.C. Bhargava recently made a striking observation, lamenting that the penetration of passenger cars in India has plateaued, despite rising income levels. Airport lounges in Delhi and Mumbai may be teeming but two traditional bellwethers of middle-class aspiration, housing and automobiles, are flashing warning lights, suggesting that consumer confidence is wavering. Wage stagnation, an acknowledged problem for some years, is compounded by the anxiety of job losses. Thus, the layoffs at TCS signal that other IT companies will soon follow suit. Across industries, from IT to banking, the spectre of redundancy has returned, this time not as a cyclical correction but as a recalibration of the number of people actually required in the emerging AI economy. The playbook that once ensured growth is in urgent need of a rewrite and, increasingly, companies are seeking new leaders to do the writing. In October last year, a McKinsey study on the changing face of leadership concluded that today's most effective leaders are those willing to embrace a 'generational shift". That means breaking away from hierarchical, matrixed organizations and building flatter, faster, and more agile operating models. That, ultimately, may explain the abrupt leadership resets at many companies as they seek to reimagine leadership in a world where yesterday's business assumptions no longer hold with a fundamental transformation in consumer behaviour, cost structures, talent models, and technological change. Only companies that accept this as a foundational shift and not a passing squall will survive and thrive. Those that don't may find that even the best CEO cannot steer a company anchored to the past.
